drugset
drugset / Trial / NCT03856099

TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

NCT03856099 ↗

Phase 2 Terminated 19 enrolled PharmAbcine
NaSequentialOpen-labelTreatment

Summary

This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.

Timeline

Start
2019-11-13
Primary completion
2022-07-15
Completion
2022-07-15

Outcome

Outcome not reported

Stopped (Enrollment): “Subject recruitment issues and follow-up study plans”

Drugs

EvaluationDrugModalityDoseRoute
Subject Olinvacimab Monoclonal antibody 16 mg/kg —
Subject Olinvacimab Monoclonal antibody 20 mg/kg —
Subject Olinvacimab Monoclonal antibody 24 mg/kg —

Indications

glioblastoma